Posted by Michael Wonder on 06 Jul 2017
Additional listings on the Pharmaceutical Schedule of a range of orthopaedic implants and associated products with Johnson & Johnson
6 July 2017 - PHARMAC is pleased to announce the approval of an amendment to the suture agreement with Johnson & Johnson.
This was the subject of a consultation letter dated 6 June 2017.
In summary, the effect of the decision is that:
- Johnson & Johnson's DePuy Synthes range of orthopaedic implants, and associated products will be listed in Section H, Part III, (‘Optional Pharmaceuticals’) of the Pharmaceutical Schedule from 1 August 2017
- DHB hospitals can purchase these items directly from Johnson & Johnson
- For the DHBs that currently use these products the national agreement will deliver savings
